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Abstract
Adverse drug reactions (ADRs) are major clinical problems, particularly in
special populations such as pediatric patients. Indeed, ADRs may be caused by a
plethora of different drugs leading, in some cases, to hospitalization, disability or
even death. In addition, pediatric patients may respond differently to drugs with
respect to adults and may be prone to developing different kinds of ADRs,
leading, in some cases, to more severe consequences. To improve the
comprehension, and thus the prevention, of ADRs, the set-up of sensitive and
personalized assays is urgently needed. Important progress is represented by the
possibility of setting up groundbreaking patient-specific assays. This goal has
been powerfully achieved using induced pluripotent stem cells (iPSCs). Due to
their genetic and physiological species-specific differences and their ability to be
differentiated ideally into all tissues of the human body, this model may be
accurate in predicting drug toxicity, especially when this toxicity is related to
individual genetic differences. This review is an up-to-date summary of the
employment of iPSCs as a model to study ADRs, with particular attention to
drugs used in the pediatric field. We especially focused on the intestinal, hepatic,
pancreatic, renal, cardiac, and neuronal levels, also discussing progress in
organoids creation. The latter are three-dimensional in vitro culture systems
derived from pluripotent or adult stem cells simulating the architecture and
functionality of native organs such as the intestine, liver, pancreas, kidney, heart,
and brain. Based on the existing knowledge, these models are powerful and
promising tools in multiple clinical applications including toxicity screening,
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Core tip: Adverse drug reactions (ADRs) are major clinical problems, especially in
pediatric patients, who may respond differently to drugs with respect to adults. This up-
to-date review focuses on the employment of patient-derived induced pluripotent stem
cells and related systems (i.e. stem cell-derived organoids) to study ADRs in adults, and
wherever available, in the pediatric field. We especially focused on the intestinal,
hepatic, pancreatic, renal, cardiac, and neuronal levels, in which the major ADRs are
usually observed. Due to their genetic and physiological species-specific differences,
these models may be accurate in predicting drug toxicity.
Citation: Genova E, Cavion F, Lucafò M, Leo LD, Pelin M, Stocco G, Decorti G. Induced
pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced
adverse events. World J Stem Cells 2019; 11(12): 1020-1044
URL: https://www.wjgnet.com/1948-0210/full/v11/i12/1020.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i12.1020
ADVERSE DRUG REACTIONS
Adverse drug reactions (ADRs) are major clinical problems[1], especially for special
populations such as pediatric patients[2,3]. Indeed, a significant number of drugs can
cause adverse effects leading, in some cases, to patients’ hospitalization, permanent
disability, or even death. ADRs are costly for pharmaceutical industries in terms of
drug withdrawal from the market[4],  but also in terms of clinical  and economical
efforts needed to resolve side effects[1]. In order to avoid these problems that affect
patients’  health and greatly increase costs related to treatment,  it  is  necessary to
improve clinical  trial  strategies.  In addition,  both in vivo  and in vitro  models are
needed  that  better  assess  and  evaluate  drug  safety.  Due  to  newly  discovered
technologies and progress made in this area, this goal seems achievable[5-7]. Indeed, to
date, it is possible to establish more sensitive and personalized assays leading to a
better comprehension, and thus prevention, of ADRs. One of the most important
advances in this field is the possibility to set up groundbreaking patient-specific
assays. Indeed, ADRs are related to individual genetic patients’ background, leading
to a wide range of toxicities of different severities[8]. Another important point is that
pediatric patients may respond differently to drugs than adults and are susceptible to
developing  different  patterns  of  ADRs,  leading,  in  some  cases,  to  more  severe
consequences[1-3].  One of the most powerful tools that can be used to individually
model drug response and ADR development is represented by induced pluripotent
stem cell (iPSC) technology, which was discovered by Takahashi et al[5] more than 10
years ago.
iPSCs can be used to evaluate safety during drug preclinical screening, possibly
replacing the use of animal models or immortalized human cell lines. Due to genetic
and physiological  species-specific  differences,  these  models  may be  accurate  in
predicting drug toxicity, especially when this toxicity is related to individual genetic
differences[9].  Indeed,  many  factors  may  influence  drug  pharmacokinetics  and
pharmacodynamics as well as the development of adverse effects, for instance: (1)
Polymorphisms in genes encoding for drug-metabolizing enzymes and transporters,
ion channels and receptors, possibly affecting their expression and/or activity[10]; (2)
Epigenetic alterations such as DNA methylation, histone modification, microRNAs,
mRNA  instability,  and  nucleosome  positioning[11];  and  (3)  Environmental  and
nongenetic factors including body mass index and behavioral patterns, concomitant
diseases, in particular liver and kidney diseases, and developmental factors, especially
those in early life[12].
In this review, we explored the state of the art of iPSCs as a model to study ADRs in
adults, and wherever available, in the pediatric field. In particular, we focused on
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intestinal, hepatic, pancreatic, renal, cardiac and neuronal levels, also discussing the
progress in the creation of organoids (Figure 1).
ADVERSE DRUG REACTIONS IN PEDIATRIC PATIENTS
Children can respond differently to many drugs and can present different ADRs than
adults[2 ,3 ].  The  reason  is  mainly  the  variation  in  the  pharmacokinetic  and
pharmacodynamic profiles between pediatric and adult patients[13,14].  In the era of
personalized medicine, it is important to screen and identify genetic variations related
to  the  predisposition  to  ADR  development  for  certain  drugs[15,16].  However,  in
pediatric patients, ADRs have not been studied as thoroughly as in adults. The clinical
and research experience on drug safety for children is limited and more works are
needed[17]. One of the reasons for the lack of these data is that, for ethical reasons, the
effects of most drugs have been analyzed in clinical trials only in adults, resulting in
limited knowledge on children’s responses[17]. To date, there is strong interest into
therapy personalization for children to further explore, study, and prevent possible
new and severe ADRs. In order to avoid the well-known ethical limitation of pediatric
trials, to increase the comprehension of drug response in children, and establish safer
and personalized treatment,  it  is  possible to use innovative technologies such as
iPSCs[5,18]. Indeed, several specific pediatric problems could be addressed using iPSCs;
for example, this technology is ideal to develop innovative patient-specific models of
rare or genetic diseases that often occur in pediatric populations[13]. Moreover, several
drugs used in pediatric patients lead to adverse effects in organs that are not easily
accessible,  such  as  pancreatitis  for  asparaginases[18]  for  the  treatment  of  acute
lymphoblastic leukemia.
INDUCED PLURIPOTENT STEM CELLS, THERAPY
PERSONALIZATION, AND ADRs
Patients’ somatic cells can be reprogrammed into iPSCs using the four Yamanaka’s
factors[5].  iPSCs preserve the donor’s genetic heritage and are useful for creating
patient-specific models[19]. For a decade, scientists have been using iPSCs to study
complex diseases and to obtain tissues or cells otherwise not simply accessible from
patients[20]. Moreover, these cells have allowed scientists to set up innovative research
to study ADRs in a more personalized way[18,21-24]. The focal point of this technology is
the  possibility  to  differentiate  iPSCs  into  almost  any  cell  of  the  human body[20].
Progress made in this last decade has allowed the development of groundbreaking
tailored models for single individuals, contributing to the modern era of therapy
personalization, finding the appropriate treatment for the right patient, and avoiding
the development of ADRs[25]. To date, a number of studies based on iPSCs for therapy
personalization and to study ADRs, especially in the adult field, are available[18,21-24].
However, more efforts are needed in the pediatric field, even though some works are
already available[26-28]. iPSCs may be a great tool to model sensitivity to new, but also
old drugs in children, shedding light on the mechanisms of toxicity, resolving in part
the problem of the lack of data. Indeed, with a simple blood sample, it is possible to
reprogram peripheral blood mononuclear cells into iPSCs that can be subsequently
differentiated into somatic cells of interest.
ORGANOIDS AS GROUNDBREAKING PATIENT-SPECIFIC
MODELS FOR PHARMACOLOGICAL STUDIES
Organoids  are  three-dimensional  (3D)  in  vitro  culture  systems  derived  from
pluripotent stem cells (embryonic stem cells or iPSCs) or adult stem cells, and can
simulate  the  architecture  and  functionality  of  native  organs[29].  Organoids  are
generated from multiple organs including the intestine[30,31],  stomach[32],  kidney[33],
liver[34],  pancreas[35],  brain[36],  and  lung[37]  and  can  be  used  in  multiple  clinical
applications including drug screening, disease modeling, and regenerative medicine.
Moreover,  the  development  of  human  patient-derived  organoids  may  enable
personalized medicine.  Considering that  organoids  cultures  based on a  specific
disease and from a specific individual can be expanded in culture maintaining a stable
genetic  and  epigenetic  signature[38],  they  are  suitable  for  biobanking  and  high-
throughput  screening.  Therefore,  organoids  represent  a  powerful  tool  for  drug
efficacy and drug toxicity screening. Future analyses may be performed using these
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Figure 1
Figure 1  iPSCs to model ADRs for therapy personalization. iPSCs: Induced pluripotent stem cells; ADRs: Adverse drug reactions. Image adapted from:
https://smart.servier.com/.
biobanks to identify new drugs, but also to know in advance which patients may
benefit from an existing drug treatment. In toxicology screenings, 3D organoids could
replace the use of  cell  lines  and animal  models.  Renal  and hepatic  toxicities  are
common in drug administration and hepato-biliary organoids generated together
with kidney organoids enable the accurate study of drug metabolism and toxicity.
Interestingly,  3D  organ-on-a-chip  is  an  experimental  system  in  which  tissue
architecture  and  cellular  composition  are  assembled  on  a  fabricated  synthetic
matrix[39]. This technology represents a novel approach to overcome the limitations of
conventional model systems, especially to model complex disorders affecting several
tissues,  and for future pharmacological  target  identification,  safety,  and efficacy
testing as well as personalized medicine.
GASTROINTESTINAL TOXICITY
Drug-induced gastrointestinal toxicity is very common and may result in different
consequences that range from nausea and dyspepsia to life-threatening events such as
the development of complicated gastroduodenal ulcers[40,41].  To study and prevent
these ADRs, researchers have started to create patient-specific in vitro models using
iPSCs. These models are based on the differentiation of iPSCs into enterocytes, using
innovative protocols, and involve the creation of groundbreaking models based on
iPSC-derived human organoids.
Intestinal ADRs
The small and large intestines are one of the most frequent sites of ADRs. The severity
of symptoms can vary from very easy-to-manage to life-threating illnesses.  Well
known  examples  of  intestinal  ADRs  are  mucosal  damage,  hemorrhage,  colitis,
changes  in  motility,  and  malabsorption[42];  an  important  example  of  frequent
gastrointestinal  ADR are  those caused by nonsteroidal  anti-inflammatory drugs
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(NSAIDs). To manage and prevent the development of intestinal ADRs, scientists
tried to model  enterocytes,  the most  abundant intestinal  cells  with fundamental
functions in nutrient/drug absorption and metabolism. In this regard, iPSCs could be
a great tool, as demonstrated by some recent works. In 2014, Iwao et al[43] generated for
the first time pharmacokinetically functional enterocytes starting from iPSCs, with the
aim of building an intestinal pharmacokinetic evaluation system to better study drug
absorption and biotransformation. The protocol developed by this group allowed the
authors  to  obtain  mature  enterocyte-like  cells  (ELCs)  after  about  30  days  of
stimulation using activin A and fibroblast growth factor (FGF)-2 in order to obtain
definitive endoderm cells. Then these immature cells were differentiated into ELCs
using epidermal growth factor in 2% fetal bovine serum. ELCs displayed increased
expression of the specific intestinal markers sucrase-isomaltase, villin 1, intestine-
specific homeobox, CDX2, dipeptidyl peptidase 4, and SLC46A1/proton-coupled
folate transporter. The authors also noticed that a longer period of differentiation
made the process more efficient in terms of the number of mature ELCs obtained.
In a subsequent study, the same group tried to ameliorate the efficiency of the
already established protocol using different small molecules[44].  In particular,  the
authors analyzed the effect of GSK-3 inhibitor XV (a highly potent inhibitor of GSK-3),
dorsomorphin (a selective bone morphogenetic protein [BMP] inhibitor), PD98059 (a
mitogen-activated protein inhibitor), 5-aza-20-deoxycytidine (an inhibitor of DNA
methylation), and A-83-01 (a potent and selective transforming growth factor beta
[TGF-β] pathway inhibitor).  Overall,  the differentiated cells  expressed intestinal
markers,  drug transporters and metabolizing enzymes, such as cytochrome P450
1A1/2  (CYP1A1/2),  CYP2C9,  CYP2C19,  CYP2D6,  CYP3A4/5,  UDP-glucuro-
nosyltransferase (UGT), and sulfotransferase. To analyze the intestinal differentiation
of iPSCs after small molecule treatment, the authors considered mRNA expression of
sucrase-isomaltase and CYP3A4, which were both markedly increased, while those of
intestinal stem cell markers decreased. In particular, CYP3A4 mRNA expression level
was mainly induced by the addition of 1α,25-dihydroxyvitamin D3. Intestinal drug
transporter  peptide  transporter  1  was  also  increased  by  PD98059,  5-aza-29-
deoxycytidine,  and  A-83-01.  With  this  work,  the  authors  created  a  model  of
enterocytes that is definitely more useful than primary cells given their poor viability,
short  life span,  limitation of passage number,  and difficulty in obtaining human
intestinal tissue samples. Moreover, ELCs seem to be a better model with respect to
the widely used Caco-2 cells, since the drug transporter expression levels and carrier-
mediated  drug  permeability  in  Caco-2  are  different  from  those  of  the  human
duodenum, and the expression level of CYP3A4 is quite low.
A similar work was performed by Ozawa et al[45], who generated an ELC monolayer
characterized by drug absorption and metabolism functions. The authors[45] analyzed
the  barrier  formation  capacity  of  the  obtained  monolayer,  measuring  the
transendothelial electrical resistance (TEER). By this test, the authors found that the
ELC  monolayers  have  a  weaker  barrier  function  than  Caco-2  cell  monolayers.
Importantly, it is known that TEER values in Caco-2 cell monolayers are higher than
those  in  the  small  intestine.  Therefore,  the  authors  concluded  that  the  ELC
monolayers might be a more suitable in vitro model for evaluating the absorption of
hydrophilic drugs than Caco-2 cell monolayers. Overall, these studies provide a basis
for exploiting ECL models to study drug absorption, metabolism, and ADRs.
Regarding our current knowledge, only a very recent work[46] applied a 2D ELC
model to study ADRs. In particular, Matsunaga’s group[46] used ELCs, obtained using
the protocol already set up and described above[43,44], to study human drug-induced
intestinal mucosal damage. In this work[46], mucin 2 (MUC2) mRNA expression as a
marker of mucosal damage was analyzed. MUC2 is the main component of intestinal
mucus and its expression in the intestine is decreased by several drugs that induce
mucosal  damage,  such  as  NSAIDs,  and  is  increased  by  other  protective  agents
including rebamipide. First, the authors compared MUC2 expression in the human
intestine, ELCs, and Caco2 cells to validate the ELC model. The results showed that
after 26 days of differentiation, ELCs presented MUC2 levels comparable to those of
the human intestine, while levels in the Caco2 line were 100 times lower. Authors also
examined the effects of NSAIDs and of the mucosal protective agent rebamipide on
MUC2 expression in the ELC model, confirming that NSAID exposure reduces MUC2
levels while rebamipide increases it. Given that the fluctuation of MUC2 seemed to be
influenced by different cytokines, they also analyzed the mRNA expression levels of
cyclooxygenase-2, interleukin (IL)-1β, nuclear factor (NF)-κB, and tumor necrosis
factor (TNF)-α after drug treatment. In particular, as reported in other studies[47-51],
they found that IL-1β, NF-κB, and TNF-α mRNA expression levels were decreased by
indomethacin, but increased by rebamipide. Therefore, taken together, the authors
concluded that  it  seems reasonable that  these factors may be involved in MUC2
expression changes in enterocytes.
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Regarding the advances for obtaining intestinal models used in drug screening,
intestinal organoids also represent a valuable tool[52]. Self-renewal of the intestinal
epithelium is driven by the proliferation of stem cells and their progenitors located in
crypt regions[30]. Wingless/integrated 3A (WNT3A), R-spondin, and noggin are factors
needed in organoid protocols to promote in vitro self-proliferation of intestinal stem
cells;  moreover,  these  organoids  are  composed  by  different  cell  types  such  as
enterocytes, Paneth cells, goblet cells, and enteroendocrine cells and manifest many
enteric characteristics[53].
Recently,  Lu  and  Rosenbaum[54]  described  the  application  of  crypt  organoid
cultures from genetically modified mice as a model to evaluate drug metabolism.
Irinotecan metabolism and toxicity were studied using crypt organoids generated
from both Ugt1F/F (control) and Ugt1ΔIEC (deletion of the Ugt1 locus) mice. These 3D
cultures metabolize the drug to the active topoisomerase inhibitor metabolite SN-38,
which is further metabolized by UGT1A1-dependent glucuronidation to form an SN-
38 glucuronide. In the absence of Ugt1 gene expression, Ugt1ΔIEC crypt cultures exhibit
very limited production of SN-38 glucuronide, concordant with increased apoptosis in
comparison with Ugt1F/F crypt cultures. Glucuronidation is an important phase II
pathway responsible for the metabolism of many drugs used also in the pediatric age,
such  as  opioids  or  acetaminophen[55].  These  results  demonstrate  that  intestinal
organoid cultures can be employed to study drug metabolism, under conditions of
altered pharmacogenetics.
Colonic organoids derived from iPSCs have been used to evaluate the toxicity of
rapamycin and geneticin; an impairment of cell proliferation was only observed after
treatment  with  rapamycin  indicating  that  this  compound can  harm the  healthy
colon[56].
Hepatic ADRs
Drug-induced liver injury (DILI) is a severe ADR characteristic of more than 1000
drugs[57]. The estimation of DILI worldwide is between 1 in 10000 and 1 in 100000
inhabitants, even though some recent studies have reported a higher occurrence[58]. In
the last several decades, the study and prevention of this ADR have gained increasing
interest in the scientific community, given its increasing incidence caused mainly by
the number of new drugs on the market[57]. Moreover, DILI is the most common cause
of drug withdrawal from the market with consequent high costs for industries[59]. DILI
is divided into acute or chronic conditions including hepatitis and acute liver failure,
leading, in the most severe cases, to liver transplant and aggressive treatments[57-60].
The mechanism of DILI development can be dose-related or idiosyncratic.
Further efforts are needed to manage and prevent this ADR, given the limitations
of current in vivo and in vitro models[61,62]. iPSCs are a great tool to overcome these
limitations and to obtain more predictive results. Indeed, several studies have already
shown how to differentiate human iPSCs into hepatocyte-like cells (HLCs) to create a
source of cells for different purposes such as in vitro drug studies. One example is the
study performed by Kondo et al[63], where iPSCs were differentiated into HLCs using a
three-step protocol, using three growth factors (activin A, hepatocyte growth factor,
oncostatin M) and two small molecules (dimethyl sulfoxide, dexamethasone). With
this work, the authors established a reproducible and relatively inexpensive method
to obtain a greater number of hepatic cells, with respect to other protocols, to perform,
for  example,  pharmacological  studies.  The  differentiated  cells  expressed  the
hepatocyte markers hepatocyte nuclear factor 4 alpha (HNF4-α), albumin (ALB), and
alpha-fetoprotein (AFP) at similar or higher levels in comparison to primary human
hepatocytes (PHH) and HepG2 cells. HLCs were also characterized by the expression
of drug metabolizing enzymes such as CYP3A4 and UGT1A1. Authors demonstrated
that the mRNA expression levels of CYP3A4 and UGT1A1 were increased by the CYP
inducers dexamethasone, rifampicin, and omeprazole. However, the expression levels
of drug-metabolizing enzymes were very low compared to those in PHH and mature
liver. Two years after Kondo’s work, Kang et al[64] confirmed the greater similarity of
HLCs and PHH, with respect to HepG2 cells, analyzing acetaminophen hepatotoxic
effects  on all  three  cell  types.  In  particular,  HLCs were  more  similar  to  PHH in
comparison  to  HepG2  cells  both  in  terms  of  cell  viability  after  acetaminophen
exposure and CYP450 levels, with similar downregulation of CYP1A2 and CYP3A4
genes by cytotoxic concentration of both agents. In contrast, HepG2 cells showed an
increment in CYP levels.
Takayama et al[21]  investigated whether HLCs, obtained differentiating iPSCs of
different  donors,  could  reproduce  the  interindividual  difference  in  hepatic
biotransformation and drug response. In this regard, HLCs were generated from
human iPSCs, established by reprogramming donor PHH. iPSCs were generated
using a non-integrative method, based on Sendai Virus vectors, a process essential to
avoid insertional mutagenesis. After this, they compared the drug metabolism and
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drug responsiveness of HLCs to those of their parental PHH. The main purpose of
this work was to establish a panel of HLCs that represents the diversity of genetic
polymorphisms in humans, in order to use these cells to determine the appropriate
drug dosage for the single individual. In particular, they focused on CYP activity
levels  in  the  HLCs with  respect  to  the  parental  PHH.  Results  showed that  CYP
activity and drug responsiveness of individual HLCs reflected those of parental cells,
suggesting that it might be possible to predict individual CYP activity using HLCs
and to perform personalized drug treatment analyzing HLCs of the single patient.
Moreover, the presence of a single nucleotide polymorphism (SNP) in genes encoding
CYP2D6, related to a different metabolism and drug responsiveness, was successfully
reproduced in HLCs. Also, Liu et al[65] successfully differentiated iPSCs into HLCs
with  a  relatively  simple  three-step  protocol,  using  the  commercial  hepatocyte
maturation medium HepatoZYME (Life Technologies, Frederick, MD, United States).
These authors reprogrammed peripheral blood mononuclear cells (PBMCs) instead of
PHH, with obvious advantages, given the greater ease of access of blood with respect
to liver biopsies. Similarly, Wilson et al[66]  generated iPSCs and then HLCs from a
cohort of individuals affected by alpha-1 anti-trypsin deficiency (AATD), a genetic
disorder related to liver cirrhosis and pulmonary emphysema and characterized by
low levels of AAT, the main protease inhibitor (PI) in human serum. In particular, the
most  common  deficient  allele  involved  in  the  development  of  AATD  is  the  PI
homozygous for the Z allele (termed PiZZ by authors). The most common disease
variant is caused by an inherited single base pair mutation of the serpin family A
member 1 gene, which results in a glutamate to lysine substitution and production of
a mutant version of the PI AAT, known as Z AAT. Interestingly, the authors found
that the global transcriptomes of iPSCs, carrying PiZZ mutations, diverge from that of
the healthy controls (three control individuals without any known disease) only after
differentiation to HLCs, when the AAT gene is expressed. Moreover, the obtained
HLCs successfully model key features of AAT-associated liver disease, including
intracellular accumulation and reduced secretion of AAT protein as well as increased
autophagic flux. The authors confirmed an increase in autophagic flux upon treatment
with the drug carbamazepine as previously described in mice carrying the mutation.
Subsequently, authors tested if the PiZZ mutation can increase the toxicity of different
drugs  with  respect  to  healthy  PHH,  and  exposed  both  HLCs  and  controls  to
acetaminophen and other drugs known to cause hepatotoxicity. In each case, HLCs
carrying the PiZZ mutations were more sensitive to drugs with respect  to PHH.
However, further studies need to be done to evaluate the cytotoxic mechanisms of
drugs in HLCs carrying the PiZZ mutations with respect to healthy HLC controls. The
authors concluded that these findings support the utility of iPSCs as tools for drug
development or prediction of toxicity. More recently, Kvist et al[67] deeply analyzed the
critical differences in drug metabolic properties of different human hepatic cellular
models including PHH, HLCs, and the hepatoma cell  lines HepG2 and HepaRG.
Surprisingly, these authors showed that HLCs, obtained differentiating iPSCs, should
not be used as a model to study drug metabolism, and thus ADRs,  since critical
differences were detected with respect to human PHH. This conclusion, in contrast
with other works[21,63,64], arises from a different analysis performed by Kvist’s group
analyzing the expression and function of  key hepatic  proteins important  for  the
metabolic fate of drugs such as CYP enzymes. A principal component analysis to
study and compare gene expression of  HLCs,  PHH, and the hepatoma cell  lines
HepG2 and HepaRG showed a distance between the two iPSC-derived hepatocytes,
as well as HepG2 and HepaRG cells, and the three PHH donors and PHH pool, which
were clustered more closely together. This finding was confirmed by another analysis,
which clustered HepG2 close to HLCs in terms of gene expression of 91 genes related
to the liver function or CYP450. Moreover, HLCs were found to have low activity of
several CYPs such as CYP3A and CYP2C9, barely detectable activity of CYP1A2, 2B6,
2C8, 2C9, 2C19, 2D6, and a high expression of several extrahepatic P450s such as
CYP1A1 and 1B1 that may have significant effects on biotransformation profiles. On
the other hand, HepaRG cells showed a CYP profile very similar to PHH, suggesting
that this cell line can be a good model in drug metabolism studies and ADRs. The
authors concluded that, to date, HLCs derived from patients’ iPSCs should not be
used as a substitute for PHH in drug toxicity studies. To improve the performance of
the HLC model, the authors suggested to culture cells in a 3D rather than the current
2D monolayer, because the 3D model has been shown to improve the performance of
PHH[68]. In 2018, Smutný et al[69] used HLCs to study the toxicity of phytochemicals
saikosaponin D, triptolide, deoxycalyciphylline B and monocrotaline known to cause
DILI, in comparison with hepatoblastoma-derived HepG2 cells and long-term culture
of primary human hepatocytes (LTHHs). In order to compare the cytotoxic effects of
the tested phytochemicals, the authors analyzed hepatocyte key markers in the HLCs
compared to  the  HepG2 and LTHHs controls.  First,  they  analyzed ALB level,  a
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specif ic  protein  produced  only  by  hepatocytes  and  hepatoblasts  by
immunofluorescence  staining  and  real  time  PCR.  Both  HLC  and  HepG2  cells
exhibited intense staining of ALB. The mRNA level of ALB in the HLC cells was
similar to that of HepG2 cells but was lower than that in reference LTHHs of the two
donors. Then, transcription of HNF4α, a liver-enriched transcription factor associated
with the regulation of many liver-specific genes, was confirmed in the HLC model, as
well as the expression of CYP3A4, which however was lower with respect to LTHHs.
Interestingly,  HepG2  cells  were  negative  for  the  important  CYP3A4  drug-
metabolizing enzymes. Additionally, the authors analyzed the maturation of HLCs
studying three markers: AFP, a typical liver marker expressed in hepatoblasts and
fetal hepatocytes, but not in adult hepatocytes; cytokeratin 19 (CK19), a marker of
cholangiocytes and hepatic progenitors; and CYP3A7, a CYP450 enzyme expressed
mainly in fetal hepatocytes and at a very low level in adult hepatocytes. Overall, the
results showed that HLCs resemble to be closer to an immature hepatic phenotype
expressing both AFP and CK19 markers. After characterizing HLCs, they analyzed
the  potential  of  HLCs,  HepG2,  and  LTHHs  to  predict  DILI  using  hepatotoxic
compounds. Overall, HLCs appeared more sensitive to triptolide and saikosaponin D
in comparison to both HepG2 cells and LTHHs. Interestingly, the authors noticed an
atypical  response  of  HepG2  cells  with  less  toxicity  at  higher  concentrations  of
triptolide. This atypical effect could be related to particular resistance mechanisms
characteristic of the HepG2 line, such as induction of metabolizing enzymes and/or
efflux transporters induced by high doses of this phytochemical. Also, saikosaponin D
treatment produced higher cytotoxic effects in HLCs, although LTHHs also showed
high sensitivity. However, the HepG2 cells resulted less sensitive to saikosaponin D
with effects observed at the highest concentration tested. Regarding monocrotaline,
no cytotoxic effect was reported in all lines tested. The authors commented that this
observation may be related to targeting by monocrotaline principally  of  hepatic
sinusoidal endothelial cells. However, it would be interesting to further explore the
causes of this resistance. Finally, they analyzed deoxycalyciphylline B effects, finding
a mild decrease in mitochondrial activity at the maximal tested concentration only in
LTHHs cells, while neither HLCs nor HepG2 exhibited any toxic effect. The authors
concluded that this study provides a basis for further in-depth studies to confirm
HLCs as a competent in vitro liver cell model for toxicological assessment; however,
further  efforts  are  needed  to  develop  HLCs  with  a  more  mature  phenotype,
expressing typical  adult  hepatocyte markers such as CYP3A4,  HNF4α,  and ALB
despite the expression of immature markers typical of fetal hepatocytes and hepatic
progenitors  such  as  AFP  and  CK19.  Another  recent  and  interesting  work  was
performed by Yamazaki and Murayama[70], which analyzed CYP450 expression levels
of commercial HLCs at different culture times. Authors found a significant increase of
CYP450 activities after 3-4 weeks with respect to HLCs cultured for 1 week. After 4
weeks, HLCs reached CYP450 levels similar to those in HepaRG cells. The increase in
activity was associated with increasing CYP450 2C9 and 2C19 mRNA levels. This
finding can help researchers perform more precise and repeatable studies on HLCs
and drugs and is in contrast with the manufacturer’s instructions that suggest the use
HLCs after 1 week of culture.
In this context, the recent development of liver organoid culture systems derived
from  iPSCs  provides  another  promising  strategy  to  study  drug-induced
hepatotoxicity[71,72]. Liver organoids closely resemble in vivo human liver, preserving
their genetic and epigenetic integrity over months in culture[73].
The most recently published method to generate functional hepatobiliary organoids
from iPSCs cultured on Matrigel was developed by Wu et al[74]. The protocol is based
on inclusion at  differentiation stages I  and II  (days 1–15)  of  25% mTeSR culture
medium into hepatic differentiation medium to induce endodermal and mesodermal
commitment; subsequently, at stage III (days 15-45), 10% cholesterol and other small
molecules (a Chinese patent pending product called cholesterol+MIX) were added to
the maturation medium to promote the formation and maturation of hepatobiliary
organoids by activating the NOTCH2 and TGF-β signaling pathways. Concerning
drug metabolic functions, the expression of several P450 enzymes was measured: the
organoids displayed significantly higher levels of CYP3A4 and CYP2E1 than fetal
liver, with comparable expression of CYP2A6, CYP2B6 and CYP2D6. On the contrary,
the expression of most P450 enzymes (except for CYP3A4) in liver organoids was
significantly lower than that in the adult liver, indicating that these organoids present
intermediate maturity between the fetal and adult liver.
Liver organoid culture systems allow hepatotoxicity testing. Recently, Leite et al[75]
established a method to detect hepatocyte-mediated and drug-induced liver fibrosis
based on this platform. After a single dose or repeated exposure for 14 days to the
pro-fibrotic compounds allyl alcohol and methotrexate, hepatic organoids displayed
fibrotic features such as activation of hepatic stellate cells (HSCs), the major collagen-
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producing cells  during conditions  of  sustained hepatic  injury.  The tested drugs
caused significant upregulation of HSC activation-associated mRNAs collagen, type I,
alpha 1,  collagen,  type I,  alpha 3,  and lysyl  oxidase homolog 2 in the organoids.
Acetaminophen is another compound identified by these organoids as an inducer of
hepatotoxic-mediated HSC activation, which was also confirmed in an in vivo model.
Pancreatic ADRs
Drug induced-pancreatitis is a serious problem for both the patient and the health
system. About 0.1%-2% of drugs are related to the development of this ADR and cases
can be mainly divided into mild and severe. Severe cases may lead to death, while
mild ones lead to patient hospitalization. Recently, our group reviewed the possible
application of iPSCs to study and prevent this ADR[18,76]. Here, we provide an up-to-
date revision of iPSC technology to model patient-specific human pancreatic cells
with the purpose to obtain a platform for drug-induced pancreatitis studies. iPSCs can
be differentiated into both endocrine and exocrine pancreatic cells applying protocols
that  provide  the  addition  of  specific  stimuli  to  the  culture  medium.  Regarding
endocrine differentiation, many protocols are available; however, the main current
limitation is the complete maturation of differentiated cells due to its lower hormone
release profiles with respect to human islets, thereby resembling more immature fetal
endocrine cells. However, to overcome this limitation, some progress has been made
in the last several years. The work published by Pagliuca et al[77] is an example of the
progress made in this field. IPSCs were differentiated into hormone-secreting cells
using a six-step protocol and cells were cultured in clusters into spinner flasks. Cells
obtained were implanted in mice, resulting, after 3-4 months, in functional β-cells and
polyhormonal cells, a particular type of early endocrine cells that appears during
pancreas development, able to secrete insulin, glucagon, somatostatin, and pancreatic
polypeptide and localized in the walls of pancreatic ducts. These cells can be a great
tool for diabetes studies and identification of new therapeutic approaches.
To the best of our knowledge, protocols regarding exocrine differentiation are
limited.  The  most  efficient,  already  described  in  our  previous  works[14,53],  was
developed by Takizawa-Shirasawa et al[78].
Even if the progress made to obtain patient-specific pancreatic cells is increasing,
the experience on the application of differentiated cells to create a platform for drug-
induced pancreatitis studies is still limited and only two works are available. Indeed,
to  date,  only  Hohwieler  et  al[79]  developed  a  model  of  3D  pancreatic  organoids
generated from iPSCs of patients with cystic fibrosis. Their work, already reviewed by
our group[18], has provided a basis for the development of new research based on this
topic. Also, Huang et al[80] developed an efficient protocol to obtain exocrine pancreatic
organoids starting from human embryonic stem cells.  On the other hand, even if
works based on iPSCs and the generation of exocrine pancreatic cells are limited,
there are several solid works concerning pancreatic organoids created from tumor
cells.  Therefore, considering these two facts,  it  is reasonable to believe that more
progress can be made in this field to fill the existing lack of pancreatic ADR studies.
NEPHROTOXICITY
Drug-induced renal injury (DIRI) is a frequent side effect, especially in critical patients
undergoing complex pharmacological treatments. DIRI is common in the pediatric
field  with  an  incidence  of  about  25%  pediatric  patients  taking  intensive
pharmacotherapy[81,82]. This high incidence is principally due to the excretory function
of the kidney, which is exposed to high concentration of drugs or metabolites. DIRI
can lead to severe acute renal failure, which contributes to prolonged hospitalization,
and  increased  costs  for  healthcare  and  morbidity.  To  prevent  devastating
consequences for patients, it is important to identify markers of this adverse event,
taking measures to avoid it. To date, the main clinical indicators of DIRI are serum
creatinine levels; however, novel markers are needed to more efficiently prevent its
development[83]. It is known that this adverse effect can be caused by drugs through
different  mechanisms  that  are  divided  on  the  basis  of  the  affected  kidney
component[84]. A major problem of DIRI management is the lack of in vitro models to
test nephrotoxicity of drugs or to find predictive biomarkers of renal drug toxicity[85,86].
iPSCs from patients represent a promising model to develop more precise therapies,
better studying the mechanisms related to drug-induced nephrotoxicity and creating
the possibility to prevent DIRI development.
The differentiation of iPSC to renal cells involves different steps: starting from
mesendoderm formation, the intermediate mesoderm can be obtained, from which it
is possible to obtain the ureteric bud or metanephric mesenchyme. From the latter, the
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differentiation continues with the renal vesicle, from which the podocyte, proximal
tubule, or distal tubule can be obtained[87]. Taguchi et al[88] analyzed a differentiation
protocol allowing metanephric nephron progenitors starting from iPSC to be obtained
in 14 days. The protocol involved different steps of differentiation: starting from the
formation of embryoid bodies (EBs), epiblast, nascent mesoderm, posterior nascent
mesoderm, posterior intermediate mesoderm, and finally metanephric mesenchyme.
The different steps were obtained with appropriate concentrations and exposure
times to stimuli added in the medium: activin-A, and bone morphogenetic protein 4
(BMP-4),  CHIR99021,  retinoic  acid,  fibroblast  growth  factor  2  (FGF-2),  FGF-9.
Immunohistochemical analysis confirmed the differentiation[89]. Xia et al[89] derived
ureteric  bud  progenitor-like  cells  from  iPSC  in  4  d.  The  culture  medium  was
supplemented with BMP-4 and FGF-2 for 2 d and then with retinoic acid, activin-A,
and  BMP-2.  The  differentiation  was  evaluated  using  real-time  PCR  and
immunostaining[89].  Musah et  al[90]  developed a differentiation method of iPSC in
kidney glomerular podocytes with a feeder-free and serum-free protocol in 21 days.
The differentiation procedure was established in three commercial iPSC lines: PGP1,
IISH3i-CB6, and IMR-90-1. During differentiation, the cells were cultured on tissue
plates coated with lamin-511 E8 fragment and the mesoderm was obtained adding
Rho-associated kinase inhibitor Y27632, CHIR99021, and activin-A; the intermediate
mesoderm was obtained with CHIR99021 and BMP-7; and finally podocytes were
obtained by  stimulating  the  cells  with  BMP-7,  retinoic  acid,  activin-A,  vascular
endothelial  growth factor  (VEGF),  and CHIR99021.  The  differentiation  markers
analyzed were goosecoid, HAND1, and brachyury in the case of the mesoderm; Pax2
for the nephron progenitor cell markers; WT1 and OSR1 for intermediate mesoderm;
and finally, for podocytes WT1, podocin, and nephrin proteins and specific genes
such as MAF, PODXL, SYNPO, and EFNB2, together with a decrease of progenitor
marker genes (e.g., SALL1 and PAX2) and pluripotency genes (such as SOX2, MYC,
NANOG, POU5F1)[90,91].  The authors also created an organ-on-a-chip microfluidic
model of glomerular function. Organ-on-a-chip culture models can better reproduce
the structure, function, and environment of human organs. The chip was formed by
two parallel micro-channels separated by a poly(dimethylsiloxane) membrane: the
intermediate mesoderm, subsequently differentiated into podocytes was cultured in
the upper part of the channel and in the opposite part the primary human glomerular
microvascular endothelial cells were seeded. In this way, it was possible to recreate
the podocyte-endothelium interface. Furthermore, two hollow chambers were added
on the sides of the central channels and a cyclic suction was applied to mimic the
cyclical pulses of the renal blood flow that cause relaxation or motion and dynamic
mechanical stretching in vitro. The podocytes were obtained by differentiation in the
presence or absence of fluid flow or with a combination of fluid flow and mechanical
strain; nephrin expression analyses indicated that differentiation may be influenced
by mechanical forces. Further analysis showed that with cultures in the presence of
flow or the flow-mechanical combination, there was an increase in the number of
processes  of  the  podocytes  and  greater  production  of  VEGF-A  (necessary  for
development of the glomerulus in vivo). They analyzed the percentages of retained
ALB and inulin filtration in the presence of cyclin mechanical strain and noted that
99% of ALB is retained while 5% of inulin is filtered, suggesting that this represents a
good  in  vitro  model  for  glomerular  filtration  barrier.  They  also  analyzed  the
production of collagen IV (mainly produced by glomerular podocytes in the mature
glomerular basement membrane) and noted that this type of collagen is produced by
both cell types present in the chip, even though the greatest production occurs in
differentiated  podocytes  under  mechanical  strain,  demonstrating  the  greater
differentiation efficiency in the presence of mechanical strain. Finally, they analyzed
the damage induced by a continuous flow of the adriamycin anti-tumor drug on this
organ-on-a-chip. The results revealed an interruption of the podocyte layer and cell
detachment in a dose-dependent manner, together with decreased viability and non-
selective loss  of  ALB from vascular  channel.  This  indicated that  the tested drug
produced lesions and that this model is useful for analyzing glomerular function,
therapeutic development, and drug-induced toxicity[91].
Kandasamy et al[92] reported an example of proximal tubular-like cell differentiation
from iPSCs used to predict drug-induced nephrotoxicity. They used commercial iPS
(foreskin)-4, from WiCell Research Institute and differentiated these cells in human
proximal tubular-like cells (HPTC-like) in 8 days, using commercial renal epithelial
growth medium supplemented with BMP-2 and BMP-7. They analyzed the expression
of markers to evaluate the different steps of differentiation in HPTC-like cells. In
summary,  the  expression  of  iPSC  characteristic  genes  such  as  SOX2,  NANOG,
DNMT3D,  and OCT3/4  decreased starting from day 1 of differentiation, while the
characteristic  genes  of  proximal  tubular  cells  (AQP1,  GGT,  and  KSP-CAD)  are
expressed in HPTC-like cells. The authors also analyzed the expression of 31 different
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genes in HPTC-like cells, including genes coding for transporters, epithelial markers
and  kidney  injury  markers.  Then  they  analyzed  the  nephrotoxic  effect  of  two
compounds, rifampicin and citrinin, in terms of IL-6 and IL-8 expression and noted an
increase in the two ILs after drug treatment. They used the IL-6/IL-8-based assay to
test  30  compounds that  included substances  for  which a  nephrotoxic  effect  was
known and substances that did not produce such toxicity and treated HPTC-like cells
derived from iPSC differentiation and a commercial line of HPTC (American Type
Culture Collection, Manassas, VA, United States). To classify the compounds as toxic
and non-toxic,  an  automated classifier  was  used and the  system was  trained to
recognize  the  two types  of  compounds.  Finally,  they  tested  how predictive  the
developed system was and concluded that cells differentiated from iPSCs have higher
test accuracy than HPTC. Therefore, HPTC-like cells can be used to predict toxicity
using this automatic system. In addition, performance predictions were also analyzed
using HPTC derived from nephrectomy samples from two tumor patients and an
increased variability in performance was observed. The authors concluded that the
use of HPTC-like cells differentiated from iPSCs in this prediction system can avoid
inter-donor variability problems and thus could be useful to predict nephrotoxicity of
drugs.  Finally,  authors  tested  the  anti-cancer  drug  cisplatin  using  different
biomarkers.  The treatment produced HPTC-like DNA double-strand breaks and
reactive oxygen species  (ROS) production.  The authors reported that  the results
obtained are in line with clinical data and animal experiments, and concluded that
iPSC-differentiated HPTC-like cells are an effective model for the in vitro study of
cisplatin-induced toxicity[92].
Although the number of studies on drug-induced nephrotoxicity based on iPSCs is
currently  limited,  such  a  model  represents  a  good  tool  to  investigate  the
pathophysiology of many renal diseases and may allow the investigation of more
effective therapies. In fact, for many kidney diseases, specific in vitro models are not
yet available. The use of pluripotent stem cells (including iPSC and embryonic stem
cells) have allowed the study of renal diseases due to genetic mutations such as renal
cysts, diabetes syndrome, Wolfram syndrome, focal segmental glomerulosclerosis,
systemic lupus erythematosus, Wilms tumor, and Alport syndrome[86].
With respect  to iPSC-derived proximal tubular cells,  3D kidney organoids are
characterized by distinct cell types such as endothelial cells, nephron progenitors, and
podocyte-like cells and are therefore promising systems for nephrotoxicity testing[93].
Recent data have shown that treatment of kidney organoids generated from human
iPSCs (CRL1502)  with  nephrotoxic  cisplatin  induced specific  acute  apoptosis  in
mature proximal tubular cells, whereas immature cells did not respond to the drug[93].
These results were further confirmed on patient-derived organoids obtained from
renal  normal  tissue  of  neoplastic  patients:  a  consistent  activation  of  caspase  3
(CASP3), an indicator of apoptosis, after 72h of incubation with cisplatin was detected
by different techniques and only tubule cells suffered after drug exposure without
affecting organoid architecture[94].
Furthermore, interesting results have been obtained when organoids derived from
cultured murine nephron progenitor cells were treated for 24 h with gentamicin at
different  concentrations;  the  percentage  of  CASP3+  cells  co-stained  with  Lotus
tetragonolobus lectin, a proximal tubule marker, selectively increased up to 80%. In
contrast, immunofluorescence analyses of cells stained for podocalyxin, a glomerulus
marker, treated with gentamicin showed no cells positive for CASP3, suggesting that
the drug caused proximal tubule injury without affecting glomerular structures[95].
The most recently published paper about kidney organoids described the use of
glomeruli isolated from iPSC-derived kidney organoids for toxicity screening[96]. The
method for isolation of intact glomeruli from kidney organoids is based on enzymatic
dissociation  of  mature  organoids  that  generates  3D  aggregates  of  podocytes
representing forming glomeruli. In particular, the cultured organoid glomeruli were
exposed to increasing concentrations of doxorubicin, and after 48 hours, activation of
the pro-apoptotic pathway was evident at the lower doses; reduction in glomerular
size following doxorubicin treatment was also detectable.
These  preliminary  results  are  encouraging;  however,  more  drugs  must  be
evaluated before kidney organoids can be used as a promising drug testing platform.
CARDIOTOXICITY
Drug-induced cardiotoxicity may be triggered by several mechanisms of action. In
general, drugs can cause different effects at the cardiac level: heart failure due to
abrupt  decrease  of  contractile  performance,  decrease  in  left  ventricular  ejection
fraction, arrhythmias, and prolonged cardiac repolarization. The latter, associated
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with a prolonged QT interval, may increase the risk of serious cardiac arrhythmias. In
most cases, the prolonged repolarization phase is caused by drug effects at the ionic
channels  or  pump levels[97].  In  general,  variations  in  the  electrical  currents  that
stimulate the contractions of cardiomyocytes (CMs) are due to alterations in the fluxes
of ions such as Ca2+, K+, and Na+ through ionic channels in cardiac cells[98]. An example
of a potentially lethal arrhythmia is the Torsade de Pointes, often determined by the
prolongation of the action potential that affects rapid K+ current by inhibition of the
ether-a-go-go-related  gene  channel  (hERG)  in  cardiac  muscle  and  is  related  to
prolongation of the QT interval[99]. Furthermore, alterations of the ions flux not only
have consequences on CM contraction,  but  suggest  oxidative stress  condition,  a
common mechanism of toxicity that may lead to apoptosis[100].
One of the major problems during new drug development in preclinical trials is
represented by the potential cardiotoxicity of the therapeutic agent[9]. Indeed, during
the registration phase of a new drug, 23% of candidates fail for this reason[101]. In this
view,  prolongation of  the QT interval  has  been suggested as  the major  problem
related  to  the  potential  cardiotoxicity  of  drugs  by  the  U.S.  Food  and  Drug
Administration  (FDA)[102].  Hence,  in  2005,  the  International  Conference  On
Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For
Human Use created guidelines for  cardiotoxicity screening in preclinical[103]  and
clinical studies[104].
Cardiotoxicity is not only a frequent cause of failure of preclinical studies for new
drugs, but can also be the cause of drug withdrawal from the pharmaceutical market.
Between 1994  and 2006,  45% of  all  drugs  removal  from the  market  were  due to
cardiotoxicity[105]. For instance, some of the most recent withdrawals from the market
of  drugs  due  to  cardiotoxic  effects  involve  sibutramine  and  rosiglitazone.  The
anorectic  sibutramine was recalled in 2010 because of  increased risk of  nonfatal
myocardial infarction and nonfatal stroke in patient with pre-existing cardiovascular
disease[106].  The anti-diabetic rosiglitazone was also recalled in 2010. Although an
increase in mortality risk has not been identified, this drug was associated with an
increased risk of myocardial infarction and heart failure[107].
Also in this case, a promising approach is the use of iPSCs. iPSCs allow patient-
specific studies, since these cells can be easily differentiated into CMs (iPSC-CMs). In
addition, iPSC-CMs have the advantage of being cryopreserved to facilitate their use
as well as being grown in large numbers and high purity[108]. Di Baldassarre et al[109]
reported three main approaches for the generation of iPSC-CMs: differentiation of the
monolayer culture system for which various protocols have been described, co-culture
of iPSCs with visceral-endoderm–like cells, and formation of embryonic bodies (3D
culture)[109]. In general, the protocols provide, as a first step, differentiation towards
the mesoderm layer by activation of WNT, activin/NODAL, and/or BMP pathways.
For example,  the combination of  CHIR99021 with differentiation factors such as
activin-A and BMP4 are used to activate the WNT pathway[97]. The activation set of
these  pathways,  together  with  the  Matrigel  sandwich method,  has  been proven
effective[110]. However, the obtained iPSC-CMs are qualitatively and quantitatively
immature compared to adult CMs. This can significantly impact the validity of in vitro
studies using these models, in terms of modeling the disease and/or prediction of the
drug effects[110].  The differences between iPSC-CMs and adult CMs are related to:
structural gene expression[111,112], structural features[113], metabolism[112], and contractile
function[113]. Very recently, Machiraju and Greenway reported successful methods for
the maturation of iPSC-CMs, including: biochemical approaches (manipulation of
growth conditions through the addition of small molecules or changes in culture
medium), environmental manipulation (through various mechanical and electrical
forces),  and  3D  approaches  (creation  of  3D  cultures  of  CMs,  called  organoids).
According to the authors, the optimal conditions of maturation can be achieved by
combining these different approaches[110].
A good example of  the use of  iPSC derived from patients  to  perform patient-
specific studies to evaluate drug toxicity was reported by Liang et al[114]. In this study,
iPSC-CMs were obtained from healthy donors and patients with inherited long QT
syndrome (LQT), familial hypertrophic cardiomyopathy (HCM) or familial dilated
cardiomyopathy.  The  authors  initially  characterized  iPSC-CMs  by  immuno-
fluorescence staining (noting that there were phenotypic differences in patients’ iPSC-
CMs compared to healthy iPSC-CMs due to the associated pathology) and ion channel
expression (noting that they are present in all types of cells and therefore potentially
able to modulate the electro-physiological responses to drugs). Then, they analyzed
divergent aspects such as the morphology of action potentials and the action potential
duration in nodal, atrial, and ventricular waveforms in all iPSC-CMs. On these cell
models, the authors showed that the iPSC-CMs of patients affected by LQT and HCM
treated with cisapride (a gastroprokinetic agent capable of blocking hERG channels)
showed a higher susceptibility to arrhythmias, suggesting that the greater sensitivity
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to  cardiotoxicity  induced  by  this  drug  could  be  associated  with  LQT  or  HCM
mutations. Thus, it is conceivable that iPSC-CMs can be used as good models for
evaluation of the patient-specific cardiotoxicity of drugs[114].
On iPSC-CMs, different physiological parameters can be monitored as a measure of
possible  toxic  outcomes  induced  by  drugs  at  the  cardiac  level.  For  instance,
continuous real-time monitoring of the beating frequency of CMs is possible thanks to
the xCELLigence Real Time Cell Analysis Cardio Instrument, a technique useful for
the dynamic monitoring of CM contraction and beating, measured by an electric field
differentially  modulated  by  the  number  of  cells  covering  the  electrodes,  their
morphology and the strength of cell attachment. Nguemo et al[115] showed that this
technique is a useful tool for characterization of the potential cardiotoxicity of drugs.
The most recent study using this tool to analyze drug-induced cardiotoxicity on iPSC-
CMs was  carried  out  evaluating  the  cardiotoxicity  of  etoposide  (ETP),  a  broad-
spectrum anti-neoplastic drug. The iPSC-CMs were treated with ETP for 48 hours
followed by 2 days of drug washing. An irreversible increase in the beating rate of
iPSC-CMs was observed with 30 and 15 μmol of ETP with alterations in the beating
profile  and  arrhythmic  beating  (measured  with  XCELLigence).  Furthermore,
treatment with 10 μmol ETP resulted in initial changes of the beating profile, that
however, returned to baseline level after drug washing. A dose-dependent increase in
the  extracellular  level  of  lactate  dehydrogenase  after  treatment  with  ETP  was
observed, indicating membrane damage in iPSC-CMs. The authors also performed
gene expression analyses (deregulation of 58 genes and upregulation of 5 miRNAs
were found), intracellular calcium handling and mitochondrial membrane potential
analyses,  immunostaining, and transmission electron microscopy (to confirm the
cytoskeletal and mitochondrial damage). Finally, they showed that the apoptosis
inhibitor, pifithrin-α, could protect iPSC-CMs from ETP-induced cardiotoxicity[116].
Another useful technique is represented by microelectrode array (MEA), a method
that allows measurement of the electric field potential (homogeneous and electrically
coupled populations) of cardiac cells[117].  The most recent study using this tool to
analyze drug-induced cardiotoxicity was carried out on a commercially available
iPSC-CM cell line (iCell CMs, Cellular Dynamics International, Madison, WI, United
States) testing 25 drugs, with or without serum in the medium, using a MEA system
to analyze the field potential duration (FPD) and arrhythmic events. In the case of
serum-free medium, only some drugs induced significant changes in FPD, nine with
an extension and four with a reduction. In the case of medium with serum, on the
other hand, the number of drugs with prolonged FPD was 11. The authors concluded
that the presence or absence of serum can affect the results;  indeed, components
present  in  the  serum such as  serum ALB can create  optical  artifacts  during this
electrophysiology  assays,  and  therefore,  this  should  be  considered  during  the
analysis[118].
Cardiotoxicity  is  a  relevant  problem  for  anti-tumor  drugs[101].  For  example,
anthracyclines, especially doxorubicin and its derivative epirubicin, are widely used
as anti-cancer drugs in hematological malignancies (e.g., lymphoblastic or aggressive
myeloblastic leukemia) and solid tumors (such as breast, endometrial and stomach
tumors).  The  cardiotoxicity  induced by  doxorubicin  can  cause  congestive  heart
failure, tachycardia and arrhythmias, asymptomatic reduction of left ventricle ejection
fraction, cardiomyopathy, and myocardial infarction[119]. The cardiotoxicity induced
by this drug acts on several levels: activation of the apoptosis pathway by alteration of
mitochondrial functions, generation of ROS, and alteration of gene transcription due
to inactivation of topoisomerase II and double-strand breaks[120].  One of the most
recent studies of cardiotoxicity induced by doxorubicin on patient-specific iPSC-CMs
was reported by Burridge et al[119]. The study was carried out in iPSC-CMs derived by
three groups of female patients: healthy controls, breast cancer patients treated with
doxorubicin or equivalent who did not experience clinical cardiotoxicity (DOX), and
breast cancer patients treated with doxorubicin or equivalent who did experience
clinical cardiotoxicity (DOXTOX). Once derived from each of these patients, iPSCs
were differentiated into iPSC-CMs that were subsequently exposed to doxorubicin to
evaluate the drug–induced cardiotoxicity. iPSC-CMs have been tested for: toxicity of
doxorubicin  by  immunofluorescent  imaging  to  assess  the  concentration  of  the
sarcomeric disarray, detecting a concentration-dependent increase in DOXTOX cells,
but not in DOX cells at 0.1 μmol, as well as an increase in beating rates, more severe in
DOXTOX cells;  (2)  cell  viability  that  was  reduced in  DOXTOX cells;  (3)  level  of
double–stranded DNA damage (by staining for phosphorylated H2A histone family
member  X),  which  was  higher  in  DOXTOX  patients;  and  (4)  oxidative  stress,
demonstrating  that  ROS  and  H2O2  production  was  higher  while  antioxidant
glutathione  levels  decreased  in  the  DOXTOX  patients.  Moreover,  the  effect  of
doxorubicin on patient-specific gene expression was evaluated by RNA sequencing
analysis. An association between homozygous non-synonymous variants in BRCA1
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and cardiotoxicity in DOXTOX patients was found.  Because of  these results,  the
authors concluded that the study of drug-induced cardiotoxicity using iPSC-CMs
allows the evaluation of its molecular mechanisms and genetic bases[119].
Another example of iPSC-CMs used to study the cardiotoxic effects induced by
anti-cancer drugs was reported by Sharma et al[121],  who investigated the tyrosine
kinase inhibitor (TKI)-induced cardiotoxicity. TKIs are anti-cancer agents that act on
the tyrosine kinase receptor by inhibiting its phosphorylation. TKIs act in terms of
proliferation, migration and survival of the cells. However, reduced left ventricular
ejection fraction, heart failure, myocardial infarction, or arrhythmias are common
cardiac adverse effects caused by TKI treatment. In this study, patient-specific iPSC-
CMs were obtained from the somatic tissues of 11 healthy individuals and 2 cancer
patients (patients with kidney cancer and treatment with sunitinib as first-line and
axitinib as second-line without significant clinical  cardiotoxicity)  to evaluate the
cardiotoxicity of 21 FDA-approved TKIs. Different endpoints were evaluated such as
cytotoxicity,  contractility,  and the effects on QT intervals.  The authors noted the
cytotoxic effects of some TKIs (sorafenib, regorafenib, and ponatinib induced the
greatest  effects)  in  iPSC-CMs  obtained  by  healthy  patients  and  there  were  no
significant differences when compared to iPSC-CMs obtained by patients treated with
sunitinib or axitinib. Regarding the effects on cell contractility, healthy iPSC-CMs
were exposed to doses lower than the drugs’ median lethal dose, and nilotinib and
vandetanib altered the beating rate. The authors concluded that before the death of
CMs, they manifested an effect on the beat profile. Finally, regarding the effects on QT
interval, prolongation of the contraction time of CMs was observed in healthy iPSC-
CMs treated with nilotinib or vandetanib, in addition to a decrease in the beating rate
and prolongation of the transitional duration of calcium. In this article, it was also
hypothesized that insulin/IGF signaling (that was upregulated after treatment with
VEGFR2/PDGFR-inhibiting TKIs)  may protect  iPSC-CMs from TKI toxicity.  The
authors  concluded  that  iPSC-CMs  can  be  used  to  evaluate  TKI-induced
cardiotoxicity[121].
The response to some drugs is different between adults and children and/or during
childhood; for example, in the case of warfarin, in pediatric patient age has a more
important effect on pharmacokinetics than polymorphisms (for example in VKORC1
or CYP2C9 genes)[122]. Hence, of crucial importance is the establishment of patient-
specific studies to evaluate the cardiotoxic potential of drugs in pediatric patients.
Also in this case, patient-specific iPSCs are a useful tool. For example, Visscher et al[123]
reported the relationship between the SNP in a panel of genes and anthracycline-
induced cardiotoxicity (ACT) in children (independent cohort of 218 patients who
included  patients  treated  with  anthracyclines  who  had  or  not  developed
cardiotoxicity). Genomic DNA was extracted from blood, saliva, or buccal swabs and
23 SNPs were selected for which an association with ACT was already known. The
results showed an association between rs17863783 in UGT1A6 and ACT, while the
association with two SNPs in SLC28A3 (rs7853758 and rs885004) and one in SULT2B1
(rs10426377) was close to being significant. They also analyzed the influence of sex
and age at the start of treatment: The variant SULT2B1 rs10426377 was associated
with  an  increased risk  of  ACT only  in  males,  while  the  two variants  of  ABCB4,
rs4148808, and rs1149222 were only associated with an increased risk in females.
Regarding age, an association with ACT was found in the case of the HNMT variant
rs17583889 in the case of younger children (< 5.3 years)[123]. This study highlights the
ability of a specific patient study to improve the risk assessment of ACT in children,
potentially helping to improve the safety of anti-cancer therapy.
With  respect  to  the  traditional  2D cell  culture,  3D-engineered human cardiac
organoids generated from stem cell-derived CMs provide another functional in vitro
model for disease modeling and drug screening. Biochemical-inducing factors can be
combined with several  tissue engineering approaches based on 3D printing and
bioscaffold technologies to direct spatial organization of 3D tissue to build human
cardiac organoids[124,125]. Despite the progress in this area, protocols for the maturation
of CMs toward an adult phenotype in defined conditions still  need to be further
elucidated.
The study published by Voges et al[126] demonstrated that human cardiac organoids
primarily  contain  CMs  and  stromal  cells  at  a  ratio  that  is  comparable  with  the
fetal/neonatal heart, and form functional sarcomere units. Moreover, these cellular
models are able to completely recover cardiac function following injury, showing
many features of regenerative neonatal heart tissue.
Fluid-ejecting 3D human ventricular-like cardiac organoid chambers (hvCOC) can
mimic physiologically complex behaviors, such as pressure-volume relationships, and
have been used for  detecting contractile  responses  to  different  pharmacological
compounds[127,128].  The hvCOC system can accurately identify inotropic effects  of
pharmacological compounds such as isoproterenol and levosimendan, with increased
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sensitivity with respect to human ventricular-like cardiac tissues strips.
The  utility  of  these  structures  has  been  additionally  demonstrated  for
environmental  contaminants  screening,  for  example  heavy  metal  and pesticide,
confirming the accurate responses to external stimuli[129].
These preliminary results demonstrate that in the future, these platforms could
provide patient-specific models for personalized drug screening to achieve optimal
therapeutic applications.
NEUROTOXICITY
Neurotoxicity can be caused by physical, chemical, or biological agents exhibiting
adverse effects at the central or peripheral nervous system level, altering its function
or structure. Neurotoxicity can affect attention, executive functions, decision making,
and memory, based on the severity and location of the injury, compromising the
quality  of  life.  Brain  functions  can  be  altered  by  drug  activation  of  different
neurotransmitter systems, including dopamine and glutamate[130].
Drug-induced neurotoxicity  is  divided,  according  to  the  damaged region,  in:
myelinopathy,  induced  by  drugs  such  as  amiodarone,  which  causes  damage  to
Schwann  cells[131];  assonopathy,  induced  by  drugs  such  as  vinca  alkaloids  (i.e.
vincristine and paclitaxel), inducing microtubule-dependent axons damage[132]; and
neuronopathy, induced by platinum-based compounds (cisplatin and oxaliplatin) due
to oxidative or mitochondrial stress resulting in death of the dorsal root of ganglion
neurons[132].
An example of ADR is represented by seizure, a serious neurological complication
that is commonly associated with treatment with antibiotics[133]. Seizures involve an
abnormal and transient discharge of neurons at the brain level. To test drug-induced
seizure-liability many models are currently available, for example acute slide assay
carried  out  on  surgical  slides  obtained  from  any  part  of  the  brain  (especially
hippocampus), organotypic slide cultures, primary central nervous system cultures,
iPSC-derived cultures. The latter are useful to study drug-induced neurotoxicity using
different in vitro techniques, such as calcium imaging and MEA. This method allows
the measurement of the electrophysiological activities of the neural networks in a non-
invasive way[134]. For instance, Odawara et al[135] used this tool to evaluate the efficiency
of response to two convulsant agents (pentilentetrazole,  a GABA blocker,  and 4-
aminopryridine, a K+-channel blocker) in an in vitro system constituted by co-cultures
of  commercial  neurons and astrocytes  derived from iPSCs.  The results  obtained
indicated that the synchronized bursts firings, indicative of functional maturation in
synaptic transmission, and the analysis of the peaks in the synchronized bursts firings
allows the neurotoxic effects of these two drugs to be distinguished. Moreover, the co-
culture improves the spontaneous activity of neuronal networks[135]. The latter result
was obtained by Ishii et al[136],  who analyzed the response to drugs (gabazine and
kaliotoxin) on synchronized burst and spontaneous firing, demonstrating that the co-
culture system is more efficient as an in vitro model than the individual cultures of
commercial astrocytes or iPSC-derived neurons[136].
One of the protocols reported in the literature for the differentiation of human
iPSCs into a mix of neurons and glia cells takes about 28 days. The first step is the
generation  of  embryonic  bodies,  followed  by  the  generation  of  neuroepithelial
aggregates (rosettes) that requires 5 days, and then the dissociation of the rosettes and
the neuronal differentiation (20 days) in a mix of neurons and glial cells. This protocol
allows heterogeneous  cultures  of  glutamatergic,  dopaminergic,  and GABAergic
neuronal cells to be obtained, together with glial cells[137]. Mukherjee et al[138] reported
that the main method of differentiation of iPSCs involves the mimics of development
signals using culture medium added with morphogens, small molecules,  and/or
growth factors.  Differentiation can occur  basically  using two different  methods:
culture in suspension in a single cell or in adhesion with the subsequent formation of
aggregates  of  embryonic  bodies  and  the  cultivation  in  medium,  allowing  the
formation of the definitive neuroectoderm and neural rosettes; and inhibition of one
important  protein of  the small  mothers  against  decapentaplegic  family in  iPSCs
cultured as a monolayer and the formation of rosettes by inhibition of BMP. The main
differences between the two methods are the efficiency of differentiation and the
duration of culture, while the involved pathways are similar (BMP/TGF-β/Wnt). The
cortical GABAergic neurons are obtained by adding, before the phase of terminal
differentiation, inhibitors of sonic hedgehog (SHH) and/or Wnt, for the dopaminergic
neurons of the caudal midbrain (mesencephalon) with the FGF-8, SHH, and Wnt
agonist, while using FGF-2 and insulin it is possible to obtain Purkinje cells[138].
Also,  for  drug-induced neurotoxicity,  as  for  other  forms of  toxicity,  there is  a
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correlation between patient-specific gene variability and the development of adverse
drug-induced effects. In line with this observation, also in this case, iPSCs offer the
advantage of specific patient studies to better understand the correlation between
gene expression and drug toxicity.
An example was described by Ohara et al[139]. In this study, iPSCs were obtained
from PBMCs or T-lymphocytes of two patients with Charcot-Marie-Tooth disease
(CMT), with a mutation of a gene encoding a mitochondrial protein (mitofusin-2), and
two healthy individuals. iPSCs were differentiated to motor neurons, noting that the
mutation also remains in the differentiated neurons, and analysis at the mitochondria
level  indicated that  the neurons derived from patients  affected by CMT present
mitochondrial  dysfunctions.  The results  showed that  two drugs (vincristine and
paclitaxel)  cause  mitochondrial  aggregation  (a  parameter  of  mitochondrial
abnormalities  to  evaluate  the  neurotoxic  effects)  in  healthy  and  CMT-derived
neurons, but the greatest effect was observed in patients. The authors concluded that
the effect of the tested drugs is different between patients and healthy donors and that
the analysis of mitochondria is a good parameter to study neurotoxicity[139].
Permanent peripheral neuropathy is the most common non-hematologic toxicity of
anti-cancer chemotherapy,  with an incidence of  around 20%-40%[140].  It  has been
hypothesized that calcium signaling, oxidative stress, or mitochondrial changes are
effects caused by anti-cancer drugs and that these effects may induce neuropathy[132].
Several studies are available on commercial cells to study neurotoxicity. Wheeler et
al[140] studied the neurotoxic effects of three anti-cancer drugs (paclitaxel, vincristine,
and cisplatin) on neurons derived from commercial  human iPSCs (from Cellular
Dynamics  International).  They  analyzed  the  neurite  outgrowth  phenotype  and
observed a dose-dependent decrease in neurite processes in the case of treatment with
the drugs (the greatest effect was observed for vincristine). Using the Caspase-Glo 3/7
assay,  drug-induced apoptosis  was  evaluated,  noting  that  the  greatest  effect  of
increased caspase activity was present in the case of treatment with cisplatin, followed
by treatment with vincristine, while paclitaxel had no effect[140]. The effect of paclitaxel
on neurite outgrowth without affecting caspase 3/7 activation was also observed by
Wing et al[141]. In this study, neurotoxicity of other anti-cancer drugs was evaluated on
two commercial human iPSC-derived neuronal cell lines: iCell® Neurons (Cellular
Dynamics  International)  and  Peri.4U  (Axiogenesis,  Cologne,  Germany),
demonstrating a differential sensitivity of neurons to different chemotherapeutics[141].
Another study carried out on Peri.4U neurons (from Axiogenesis) is reported by Rana
et  al[142],  who studied the  effect  of  16  chemotherapeutic  agents.  One of  the  most
important  findings  was  that  some  drugs  such  as  epothilone,  taxane,  and  vinca
alkaloid chemotherapeutics did not produce cytotoxicity even though a reduction in
the length of the neurite was observed[142].
Snyder  et  al [ 1 4 3 ]  evaluated  the  neurotoxic  effects  of  different  classes  of
chemotherapeutics on various commercial neurons derived from iPSC: Peripheral
iPSC-neurons  (Axiogenesis),  iCell®  Neurons  (Cellular  Dynamics  International),
ReproNeuro glutamatergic neurons (ReproCell,  Glasgow, United Kingdom), and
human cerebral cortical neurons (Axol Bioscience, Cambridge, United Kingdom).
Initially, they evaluated the expression of the characteristic markers of each type of
iPSC neurons by gene expression and protein quantification, while the neurotoxic
effect of the compounds was evaluated as neurite dynamics and apoptosis[143].
Another example was reported by Yamada et al[144], who evaluated the neurotoxicity
and  the  influence  on  neuronal  development  of  neuronal  cells  derived  from
commercial iPSCs of 5-fluorouracil. These cells have been used as an in vitro model of
human fetal stage. Real-time PCR results showed that this drug has inhibitory effects
on the early neural differentiation of iPSCs. All of these studies have shown that
commercial neurons derived from iPSC may be useful models for the study of drug-
induced neurotoxicity, especially chemotherapeutics.
Considering the different physiological characteristics between children and adults,
particular care should be taken in the investigation of ADRs in children, also in the
case of drug-induced neurotoxicity. An example is represented by anesthetics, as
children  seem to  be  more  vulnerable  to  the  adverse  effects  of  these  drugs.  The
problem arises by the fact that many of the anesthetic protocols used in children were
developed because of those used in adults[145]. Numerous studies have indicated that
neuronal damage due to anesthetic depends on many factors such as duration of
exposure, developmental phase at the time of exposure, activated receptor subtype,
and dose and route of administration. These agents can damage immature neurons,
inducing  morphological  changes  and  functional  impairment  of  mitochondria,
releasing ROS that can further damage the tissue[146].
Neurotoxicity induced by chemotherapy is another problem in children as it may
compromise the quality of life and longevity. For example, vincristine is used for ALL,
which is the most common childhood cancer. However, this drug causes motor and
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sensory dysfunction and neuropathic  pain.  Diouf  et  al[147]  performed genotyping
analysis on two cohorts of pediatric patients with ALL treated with vincristine and
noted that the rs924607 polymorphism (CEP72 gene) could be associated with the
development of vincristine-induced neuropathy. Analysis of the neurite development
such as outgrowth, number of processes and number of branches on commercial iCell
neurons derived from iPSC (Cellular Dynamics International) showed a relationship
between CEP7  gene expression and vincristine-induced neurotoxicity;  a reduced
expression of this gene was associated with a greater sensitivity to the drug. This may
suggest  that  patient-specific  therapy  would  be  required  for  a  safer  use  of  vin-
cristine[147].
Considering the extreme complexity of the 3D structure of the brain, the study of its
development and modeling of disease processes in 2D cultures could have several
limitations.  Therefore,  the  use  of  human iPSCs for  the  generation of  3D in  vitro
organoids  has  revolutionized  the  research  in  this  field  by  recapitulating  the
organization of different regions of the nervous system such as retina, cerebral cortex,
and choroid plexus[148-150].  The protocol described by Lancaster and Knoblich[148]  to
develop cerebral  organoids begins with the generation of  embryoid bodies from
iPSCs. Embryoid bodies are subjected to neural induction in a culture medium that
favors only the neuroectoderm to expand and are then transferred into droplet of
Matrigel, which allows outgrowth of neuroepithelial buds. In the end, the tissues are
moved to a spinning bioreactor, or in an orbital shaking plate, which contributes to
increase oxygen and nutrient interchange and further development into defined brain
regions.
Human brain organoids provide insights into the pathogenesis of neurological
disorders and may offer new approaches for investigating the mechanism of the
neurotoxicity of drugs. For instance, Liu and collaborators[151] used this in vitro model
to study the neurotoxic effects of vincristine treatment. In particular, human iPSC
(SC101A-1) were cultured to generate cerebral organoids and subsequently were
treated with different concentrations of vincristine for 48 hours; the treatment resulted
in a dose-dependent growth inhibition evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide test and caused the enhanced expression of cleaved
caspase 3, indicating the induction of apoptosis[151]. In the same paper, several cellular
markers were analyzed in cerebral organoids exposed to the drug, highlighting the
inhibition  of  the  microtubule-associated  protein  tubulin,  fibronectin,  and  the
downregulation of matrix metalloproteinases 10.
Another recent report published by Huang et al[152] describes the cerebral organoids
as an innovative tool to investigate the toxicity of drugs. The authors showed that
tranylcypromine, which is used to treat refractory depression, caused neurotoxicity on
brain organoids generated from human iPSCs (SC101A-1), leading to a decreased
proliferation activity and apoptosis  induction[152].  These data were confirmed by
measuring the expressions of the neuron-specific markers TUJ1 and GFAP, which
stained for neurons and astrocytes respectively: tranylcypromine treatment impaired
cell density and arrangement affecting both cell types. Moreover, tranylcypromine
treatment abolished the transcriptional activity of BHC110/LSD1-targeted genes and
increased the expression of histone di-methylated K4.
Limits of iPSCs
One of the first problems that can be highlighted regarding iPSCs technology is the
low efficiency in reprogramming. The most important problem is related to the use of
viral vectors such as retrovirus and lentivirus, which deliver the reprogramming
transcription factors by integration in the host cell genome, leading to chromosomal
instability and tumorigenesis from insertional mutagenesis.
However,  during  the  past  several  years,  new  safer  and  non-integrative
reprogramming  methods  have  been  developed,  reaching  better  efficiency  and
avoiding the already mentioned issues. Another interesting point to discuss regards
epigenetic memory and clonal variability. iPSCs can present an epigenetic memory of
the parent somatic cells that can influence the differentiation propensity and therefore
the outcomes of studies applied to this technology. This peculiarity of iPSCs, not
characteristic of ESCs, may predispose them to differentiate more readily into their
parental cells than others and can be useful for example in cell replacement therapy.
Kim  et  al [ 1 5 3 ]  observed  in  iPSCs  obtained  by  transcription  factor-based
reprogramming, a residual DNA methylation pattern characteristic of the parent cells,
which increase their propensity to differentiate along lineages related to the donor
tissue, while restricting alternative cell fates. The authors tried to reset the epigenome
of the parent tissue by differentiation and serial reprogramming, or by treatment of
iPSCs with chromatin-modifying drugs. These approaches could help researchers in
increasing the differentiation efficiency of iPSCs, limiting the problem related to
epigenetic memory. However, other aspects could affect epigenetic memory of iPSCs,
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such as the number of passages performed. For example, Polo et al[154] demonstrated
that  increasing  the  number  of  passages  there  is  a  decrement  in  differentially
methylated regions with respect  to  the parent  cells.  One of  the reasons that  can
explain the spontaneous loss of epigenetic memory was postulated by the authors;
probably, the loss of parent cells pattern is based on a slow replication-dependent
process. However, further studies must be performed to consolidate this hypothesis
as  indicated by authors  and,  to  date,  the  origins  of  epigenetic  loss  remain to  be
determined.
Another important point related to iPSCs limits is the intra-variability differences of
clones of the same patient. Thatava et al[155]  addressed this problem analyzing the
variation in terms of pancreatic beta-cells differentiation of three iPSCs clone lines of
three patients suffering from type 1 diabetes. Interestingly, a notable intra-patient
variation,  comparable  to  interpatient  one,  was  identified  by  authors  leading  to
conclude the necessity for a comprehensive fingerprinting of multiple patient-specific
clones to obtain a representative pool of cells useable for biomedical applications such
as ADRs studies. In addition to Thatava study, also Yokobayashi et al[156] found that
the efficiency in iPSCs clones differentiation capability into primordial germ-cell was
different; in particular, they observed that the XX clones were less efficient in germ-
cell differentiation. However, interindividual variability is more important to consider
than intraindividual variation for complex genetic disorders[157].  Deneault et al[158]
analyzed both types of variabilities in iPSCs-derived neuron cells of patients with
autism spectrum disorder, a heterogeneous and complex genetic condition, finding
significant intra-variability only on few lines, corroborating what has just been said.
Concluding,  given the  contrasts  still  present  on this  aspect,  the  intra-variability
between different iPSCs clones should be investigated and it is advisable to analyze
the genetic and epigenetic features of the clones generated. To study ADRs, the clonal
variability is a key point to keep in mind in order to set up useful standardized tools.
Therefore, before developing a model useful to predict patients’ sensitivity, different
clones  should  be  first  genetically  checked to  exclude  for  instance  chromosomic
aberrations,  alterations  in  differentiation  efficiency  and  variability  in  DNA
methylation profiles. Also, the sensitivity to the drugs of interest should be analyzed
in the different clones from the same patients, to exclude a variability in the response.
Besides iPSCs, the direct differentiation of somatic cells could be used to obtain the
cells of interest. This approach has both advantages and limitations with respect to
iPSCs technology regarding the study of ADRs (Table 1). A great advantage of direct
differentiation is the short period of time necessary to obtain the cells of interest,
avoiding the iPSCs step. Moreover, using this direct method, all  DNA instability
problems in generating and expanding iPSCs, such as point mutations and karyotypic
abnormalities, can be avoided. In addition, to study ADRs affecting aged populations,
it is desirable to obtain cells reflecting the disease-related DNA mutations together
with the age of the patient. However, there is still an open debate if the best method to
recapitulate  the  age  of  the  patient  is  the  iPSCs  technique  or  the  somatic  direct
differentiation[159]. The direct method has also several limitations; iPSCs have a higher
proliferation capacity and they can self-replicate in culture differently from parental
primary cell lines used in the direct method that can be cultured for a very short time
with fast accumulation of epigenetic changes. Regarding ADR studies, it is important
to generate a great number of differentiated cells of interest and this purpose can be
more easily achieved with iPSCs rather than with the direct method based on the
great expandability of iPSCs, as discussed above. Heterogenicity of the differentiated
cells is another critical point for both techniques. This point is particularly critical for
cell  therapy and there  are  several  works  trying  to  ameliorate  this  aspect.  Some
limitations have to be underlined also for organoid technology: the complex culture
medium contains a cocktail of growth factors and molecular inhibitors which might
affect the drug responses of organoids; the extracellular matrix Matrigel, used to grow
the organoids,  might  hamper drug penetration and limit  their  potential  in  drug
screening; genetic and epigenetic aberrations might occur during long-term culture
making organoids unsuitable for transplantation/regenerative medicine. Therefore,
further  efforts  are  needed to  overcome these  limits  and improve this  promising
technology for clinical applications.
CONCLUSION
ADRs are one of the major clinical problems, especially in populations at risk, such as
pediatric patients. One of the most important tools to improve the comprehension,
and  thus  the  prevention,  of  ADRs,  is  represented  by  the  possibility  to  set  up
groundbreaking patient-specific assays. This goal has been powerfully achieved using
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Table 1  Main differences of differentiation techniques based on iPSCs and direct somatic
differentiation technologies
iPSCs Direct somatic differentiation
Reprogramming time Long Not necessary
Differentiation time Long Brief
DNA instability Occasional Rare
Proliferation of pre-differentiated cells High (iPSCs) Low (e.g., fibroblasts)
Self-renewal of pre-differentiated cells Yes (iPSCs) No (e.g., fibroblasts)
Heterogenicity of the differentiated population Critical Critical
iPSCs: Induced pluripotent stem cells.
iPSCs, being characterized by genetic and physiological patient-specific differences
and being able to be differentiated ideally into all the tissues of human body. The
knowledge  gained so  far  has  demonstrated that  iPSCs  can  be  fruitfully  used in
multiple clinical applications, including not only toxicity screening in the frame of
ADRs characterization, but also disease modelling, personalized and regenerative
medicines.  In  addition,  the  recent  development  of  related  models,  such  as  3D
organoids  derived  from  pluripotent  or  adult  stem  cells,  resembling  the  3D
architecture of different organs in a more physiological way, has paved the way to
better characterize ADRs in a personalized way.
It should be considered that the number of studies on this topic is still limited,
especially concerning the pediatric field. In this case, particular care should be taken,
considering  that  children  are  a  population  at  risk  for  ADRs and because  of  the
difficulties to obtain biological materials necessary to establish iPSCs models or stem
cells-based organoids. However, based also on studies carried out on these models
derived from adult patients or by commercial suppliers, a major advancement has
been  made  to  develop  and  establish  differentiation  procedures  to  obtain  more
efficient  differentiation protocols  and toxicity  screening methods.  It  is  therefore
conceivable  that  in  the  near  future,  thanks  to  this  progress,  also  the  number  of
pediatric studies will increase, enabling the possibility to efficiently study and predict
ADRs also in pediatric patients.
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